Netherlands· NL-3ca397a63704

Vimpat 50 mg filmomhulde tabletten

A lacosamide product containing lacosamide, registered in Netherlands by UCB Pharma S.A.. The same ATC class is registered in 18 of our 19 countries.

ATC N03AX18

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about lacosamideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Lacosamide is registered in 18 of 19 countries.

Countries holding a registration under ATC N03AX18 (lacosamide), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
10 of them publish a price we can compare per daily dose

Search lacosamide products by name

Lacosamide · ATC N03AX18

18 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Italyprice
Japan
Netherlands
Norwayprice
Polandprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lacosamide costs, country by country.

Normalised to the WHO defined daily dose (0.3 g), the median price runs from $0.48 in United States to $3.11 in Switzerland — a ×6.4 gap.

4 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown
US figures are pharmacy acquisition cost (CMS NADAC), not retail

Open the full comparison — free account Drug prices for market access

Lacosamide · price per daily dose (0.3 g)

USD · FX 28 Sept 2026

CH Switzerland$3.11
IT Italy$3.06
FR France$1.49
US United States$0.48 (acquisition cost)

Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: LACOSAMIDE
Manufacturer: UCB Pharma S.A.
Country: Netherlands (NL)
ATC code: N03AX18
ATC class: Lacosamide
Defined daily dose: 0.3 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/08/470

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

62 interactions on record for lacosamide.

Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check lacosamide against other medicines How interaction checks work

Lacosamide · interactions on record

62 records

5 severe
32 moderate

Most severe, free to view

DolasetronA04AA04severe
CeritinibL01ED02severe
CeritinibL01XE28severe
SiponimodL04AA42severe

25 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lacosamide in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lacosamide products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

Austria · Lacopat, Lacopat Packung Zur Behandlungseinleitung
Belgium · Lacosamid Hikma, Lacosamide Eg
Bulgaria · Канилад, Лакозамид Гриндекс
Cyprus · Kanilad, Lacosadel
Czechia · Arkvimma, Kanilad
Germany · Kanilad, Lackepila
Denmark · 200 mg, Lacosamid Opko Health Spain
Estonia · Kanilad, Lacosamide Alembic
Spain · Balmid, Kanilad
Finland · Lacosamide Fresenius Kabi, Lacosamide Grindeks
France · Lacosamide Arrow, Lacosamide Biogaran
United Kingdom (Northern Ireland) · Lacosamide, Lacosamide Amarox
Greece · Anlamyl, Josamec
Croatia · Kanilad, Lacosamide Grindeks
Hungary · Anlamyl, Arkvimma
Ireland · Lacosamide Ascend, Lacosamide Fresenius Kabi
Iceland · Josamec, Lacosamide Accord
Italy · Lacosamide Aurobindo, Lacosamide Doc
Liechtenstein · Lacosamid Fresenius Kabi, Lacosamide Accord
Lithuania · Lacosamide Fresenius Kabi, Lacosamide Grindeks
Luxembourg · Lacosamide Eg
Latvia · Kanilad, Lacosamide Fresenius Kabi
Malta · Anlamyl, Kanilad
Norway · Lacosamide Accord, Lacosamide Fresenius Kabi
Poland · Arkvimma, Epilantin
Portugal · Lacosamida Alter, Lacosamida Aristo
Romania · Lacosamidă Teva
Sweden · Lacomed, Lacosamide 1a Farma
Slovenia · Lacosabil, Lacosamide Grindeks
Slovakia · Arkvimma, Kanilad

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/ab91c764-b7d9-457e-9df1-8bbf5633e8b2
GET /v1/drugs/ab91c764-b7d9-457e-9df1-8bbf5633e8b2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/vimpat-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Lacosamide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp100297",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSPOVIDON (E 1202)",
    "HYDROXYPROPYLCELLULOSE, LAAG GESUBSTITUEERD (E 463a)",
    "HYPROLOSE (E 463)",
    "IJZEROXIDE ROOD  (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "INDIGOKARMIJN ALUMINIUMLAK (E 132)",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLYVINYLALCOHOL (E 1203)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "LACOSAMIDE"
  ],
  "leaflet_url": null,
  "authorised_at": "2008/08/29",
  "procedure_number": "EMEA/H/C/000863",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/08/470",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about lacosamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console